Halozyme Therapeutics, Inc. (HALO) Reports In-Line Q2 EPS

August 7, 2013 4:08 PM

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found